Biosimilar guidance prompts reviews of patent protection

Source: BIO SmartBrief

The FDA’s recently released guidance for the approval of biosimilar drugs is prompting biotech and pharmaceutical firms to evaluate their patent positions and consider greater use of methods such as keeping trade secrets to protect their intellectual property, according to patent lawyer Konstantin Linnik. Companies also will attempt to extend the protection of blockbuster drugs by developing “biobetter” products, or improved versions of existing drugs, Linnik said. Mass High Tech (Boston) (2/15)

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: